

Peter P Toth

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/387906/publications.pdf](https://exaly.com/author-pdf/387906/publications.pdf)

Version: 2024-02-01

259
papers

13,527
citations

17587

60
h-index

24864

104
g-index

273
all docs

273
docs citations

273
times ranked

14102
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. JAMA - Journal of the American Medical Association, 2013, 310, 2061.	6.9	597
2	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 2011, 5, 133-140.	1.5	592
3	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 2011, 5, S1-S8.	1.5	417
4	Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. Journal of the American College of Cardiology, 2013, 62, 732-739.	5.5	341
5	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology, 2014, 171, 309-325.	1.6	321
6	Position paper Statin intolerance "an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science, 2015, 1, 1-23.	0.9	318
7	Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology, 2011, 5, S9-S17.	1.5	299
8	High-density lipoproteins: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2013, 7, 484-525.	1.5	282
9	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews, 2017, 75, 731-767.	5.9	246
10	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	1.5	240
11	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 101161ATV00000000000000153.	3.9	229
12	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Archives of Medical Science, 2017, 5, 965-1005.	0.9	213
13	Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology, 2020, 4, 100130.	3.4	179
14	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Medicine, 2015, 13, 229.	5.6	177
15	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vascular Health and Risk Management, 2016, 12, 171.	2.2	175
16	Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management, 2012, 8, 415.	2.2	174
17	Analysis of vitamin D levels in patients with and without statin-associated myalgia " A systematic review and meta-analysis of 7 studies with 2420 patients. International Journal of Cardiology, 2015, 178, 111-116.	1.6	157
18	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology, 2016, 225, 184-196.	1.6	157

#	ARTICLE	IF	CITATIONS
19	Statin therapy and plasma coenzyme Q10 concentrationsâ€”A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 99, 329-336.	7.1	154
20	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	6.8	151
21	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, 433-442.	0.8	149
22	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. <i>Atherosclerosis</i> , 2016, 253, 194-208.	0.8	149
23	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. <i>European Heart Journal</i> , 2015, 36, 22-30.	2.2	148
24	Management of Statin Intolerance in 2018: Still More Questions Than Answers. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 157-173.	2.3	135
25	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.8	130
26	Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. <i>Clinical Nutrition</i> , 2020, 39, 1742-1752.	5.0	118
27	High-Density Lipoprotein and Cardiovascular Risk. <i>Circulation</i> , 2004, 109, 1809-1812.	6.2	116
28	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1565.	6.9	114
29	Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. <i>Clinical Therapeutics</i> , 2004, 26, 1355-1367.	2.2	113
30	Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. <i>Atherosclerosis</i> , 2015, 242, 243-250.	0.8	107
31	Natural approaches in metabolic syndrome management. <i>Archives of Medical Science</i> , 2018, 14, 422-441.	0.9	104
32	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014, 8, 148-172.	1.5	101
33	Prevalence of dyslipidemia and associated risk factors in Turkish adults. <i>Journal of Clinical Lipidology</i> , 2014, 8, 206-216.	1.5	101
34	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	7.1	101
35	Trends in Lipids, Obesity, Metabolic Syndrome, and Diabetes Mellitus in the United States: An NHANES Analysis (2003â€”2004 to 2013â€”2014). <i>Obesity</i> , 2019, 27, 309-314.	3.1	100
36	Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. <i>Frontiers in Pharmacology</i> , 2015, 6, 299.	3.6	99

#	ARTICLE	IF	CITATIONS
37	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100009.	3.4	96
38	C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. <i>Current Atherosclerosis Reports</i> , 2003, 5, 341-349.	4.7	93
39	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapyâ€”A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	7.1	92
40	Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. <i>Current Pharmaceutical Design</i> , 2018, 24, 239-258.	1.8	90
41	Introducing the â€˜Druceboâ€™™ effect in statin therapy: a systematic review of studies comparing reported rates of statinâ€”associated muscle symptoms, under blinded and openâ€”label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	7.3	89
42	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Realâ€”World Administrative Claims Analysis of Statinâ€”Treated Patients With High Residual Cardiovascular Risk. <i>Journal of the American Heart Association</i> , 2018, 7, e008740.	3.8	87
43	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100335.	3.4	86
44	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.4	85
45	Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1152-1160.e2.	1.5	85
46	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1397-1408.	5.3	85
47	Systematic Review of Lowâ€”Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.8	83
48	The â€œGood Cholesterolâ€” <i>Circulation</i> , 2005, 111, e89-91.	6.2	79
49	Coronary heart disease risk: Low-density lipoprotein and beyond. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 181-194.	5.2	77
50	The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2012, 11, 109.	6.8	76
51	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 206-212.	3.4	74
52	<scp>PCSK9</scp> inhibitor access barriersâ€”issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , 2017, 40, 243-254.	1.9	74
53	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017, 135, 1819-1831.	6.2	72
54	Reverse cholesterol transport: High-density lipoproteinâ€”™s magnificent mile. <i>Current Atherosclerosis Reports</i> , 2003, 5, 386-393.	4.7	69

#	ARTICLE	IF	CITATIONS
55	Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. <i>Current Atherosclerosis Reports</i> , 2018, 20, 20.	4.7	69
56	Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 41-49.	1.8	68
57	Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.8	66
58	Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 453-461.	4.9	65
59	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016, 107, 360-371.	7.1	62
60	Non-High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1960-1965.	5.5	61
61	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 353-368.	4.9	61
62	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	1.8	61
63	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	7.1	60
64	Molecular mechanisms of statin intolerance. <i>Archives of Medical Science</i> , 2016, 3, 645-658.	0.9	58
65	Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. <i>Journal of Clinical Lipidology</i> , 2019, 13, 100-108.	1.5	58
66	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 576-582.	1.5	57
67	The Therapeutic Role of Niacin in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 141-158.	2.1	56
68	Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. <i>Atherosclerosis</i> , 2014, 235, 585-591.	0.8	56
69	Cardiovascular Risk and Statin Therapy Considerations in Women. <i>Diagnostics</i> , 2020, 10, 483.	2.7	56
70	Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Mid-Life: The Very Large Database of Lipids (VLDL-10B). <i>Journal of the American Heart Association</i> , 2014, 3, e000851.	3.8	55
71	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. <i>Clinical Nutrition</i> , 2020, 39, 3677-3686.	5.0	55
72	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1966-1976.	1.8	54

#	ARTICLE	IF	CITATIONS
73	Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 175.	3.0	53
74	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. <i>Journal of Medical Economics</i> , 2017, 20, 555-564.	2.1	49
75	Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1670-1680.	2.8	49
76	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.8	47
77	Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. <i>Diabetes Care</i> , 2019, 42, 2307-2314.	9.0	47
78	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	3.0	47
79	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1597-1605.	1.8	47
80	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	2.8	46
81	The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. <i>Lipids in Health and Disease</i> , 2015, 14, 29.	3.0	44
82	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2015, 132, 667-676.	6.2	44
83	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 972-985.e9.	1.5	44
84	Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease. <i>Current Vascular Pharmacology</i> , 2014, 12, 653-657.	1.5	44
85	Drug Treatment of Hyperlipidaemia. <i>Drugs</i> , 2010, 70, 1363-1379.	10.8	43
86	High-density lipoprotein subfractions: current views and clinical practice applications. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 329-336.	6.9	43
87	Altlix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. <i>Nutrients</i> , 2019, 11, 2580.	4.1	42
88	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 40-52.	3.6	42
89	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	7.3	42
90	Prevalence of US Adults with Triglycerides ≥150 mg/dl: NHANES 2007-2014. <i>Cardiology and Therapy</i> , 2020, 9, 207-213.	2.6	41

#	ARTICLE	IF	CITATIONS
91	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787761.	2.4	41
92	Ten things to know about ten cardiovascular disease risk factors – 2022. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100342.	3.4	41
93	Productivity losses associated with cardiovascular disease: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 759-769.	1.4	40
94	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. <i>European Cardiology Review</i> , 2020, 15, 1-9.	2.2	40
95	Very Large Database of Lipids: Rationale and Design. <i>Clinical Cardiology</i> , 2013, 36, 641-648.	1.9	39
96	Combination therapy in dyslipidemia: Where are we now?. <i>Atherosclerosis</i> , 2014, 237, 319-335.	0.8	39
97	Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. <i>Lipids in Health and Disease</i> , 2016, 15, 28.	3.0	39
98	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. <i>BMC Medicine</i> , 2017, 15, 83.	5.6	39
99	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. <i>Metabolites</i> , 2020, 10, 392.	3.0	39
100	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	1.9	37
101	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2017, 120, 1521-1527.	1.5	37
102	Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. <i>Clinical Biochemistry</i> , 2019, 64, 24-29.	2.0	37
103	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019, 115, 204-212.	3.6	36
104	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 279-289.	4.5	36
105	Emerging LDL therapies: Mipomersen – antisense oligonucleotide therapy in the management of hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, S6-S10.	1.5	35
106	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179.	4.6	35
107	There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100371.	3.4	34
108	Update on the efficacy and safety of combination ezetimibe plus statin therapy. <i>Clinical Lipidology</i> , 2010, 5, 655-684.	0.4	33

#	ARTICLE	IF	CITATIONS
109	Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia. <i>Clinical Cardiology</i> , 2015, 38, 483-491.	1.9	33
110	Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. <i>Journal of Clinical Lipidology</i> , 2019, 13, 634-644.	1.5	33
111	Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. <i>Current Pharmaceutical Design</i> , 2017, 23, 2496-2503.	1.8	33
112	Drug therapy for hypertriglyceridemia: Fibrates and omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2009, 11, 71-79.	4.7	32
113	Novel Therapeutic Targets for Managing Dyslipidemia. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 733-747.	8.4	32
114	The Relationship between COVID-19 and Hypothalamicâ€Pituitaryâ€Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excessâ€The CAPISCO International Expert Panel. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7326.	4.1	32
115	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 107-116.	1.5	31
116	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. <i>Current Atherosclerosis Reports</i> , 2020, 22, 18.	4.7	31
117	Physical activity, cardiorespiratory fitness, and cardiovascular health: A clinical practice statement of the American Society for Preventive Cardiology Part I: Bioenergetics, contemporary physical activity recommendations, benefits, risks, extreme exercise regimens, potential maladaptations. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100424.	3.4	31
118	Effect of Evolocumab on Lipoprotein Particles. <i>American Journal of Cardiology</i> , 2018, 121, 308-314.	1.5	30
119	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. <i>Vascular Health and Risk Management</i> , 2013, 9, 719.	2.2	29
120	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1248-1258.	1.5	29
121	Association Between Smoking and Serum GlycA and Highâ€Sensitivity Câ€Reactive Protein Levels: The Multiâ€Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSAâ€Brasil). <i>Journal of the American Heart Association</i> , 2017, 6, .	3.8	29
122	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. <i>BMC Medicine</i> , 2021, 19, 139.	5.6	29
123	Drug safety evaluation of rosuvastatin. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 969-986.	2.4	28
124	Effect of Evolocumab on Nonâ€Highâ€Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014129.	3.8	28
125	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 1-8.	0.8	27
126	HDL Hypothesis: Where Do We Stand Now?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 398.	4.7	25

#	ARTICLE	IF	CITATIONS
127	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. <i>Lipids in Health and Disease</i> , 2016, 15, 22.	3.0	25
128	Bioresorbable scaffold "A magic bullet for the treatment of coronary artery disease?. <i>International Journal of Cardiology</i> , 2016, 215, 47-59.	1.6	25
129	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	3.4	25
130	Antisense therapy and emerging applications for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, 441-449.	1.5	24
131	Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. <i>Vascular Health and Risk Management</i> , 2012, 8, 39.	2.2	24
132	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. <i>Clinical Lipidology</i> , 2013, 8, 13-41.	0.4	24
133	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	10.8	24
134	Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 1-10.	1.3	24
135	High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects. <i>Disease-a-Month</i> , 2001, 47, 365-416.	1.2	23
136	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	7.1	22
137	Pasta Supplemented with <i>Opuntia ficus-indica</i> Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. <i>Metabolites</i> , 2020, 10, 428.	3.0	22
138	Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 1204-1211.	1.5	21
139	Adiponectin and high-density lipoprotein: a metabolic association through thick and thinThe opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2005, 26, 1579-1581.	2.2	20
140	Making a Case for Quantitative Assessment of Cardiovascular Risk. <i>Journal of Clinical Lipidology</i> , 2007, 1, 234-241.	1.5	20
141	A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia) therapy for dyslipidemia?. <i>Journal of Clinical Lipidology</i> , 2008, 2, 313-317.	1.5	20
142	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016, 111, 343-356.	7.1	20
143	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGAM2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.4	20
144	Physical activity, cardiorespiratory fitness, and cardiovascular health: A clinical practice statement of the American Society for Preventive Cardiology Part II: Physical activity, cardiorespiratory fitness, minimum and goal intensities for exercise training, prescriptive methods, and special patient populations. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100425.	3.4	20

#	ARTICLE	IF	CITATIONS
145	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. <i>Journal of Clinical Lipidology</i> , 2012, 6, 180-191.	1.5	19
146	LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. <i>Postgraduate Medicine</i> , 2022, 134, 752-762.	2.0	19
147	The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1452-1461.	1.5	18
148	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	7.1	18
149	Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2022, 9, 100318.	3.4	18
150	Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.8	18
151	Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. <i>Atherosclerosis</i> , 2014, 237, 790-797.	0.8	17
152	Activation of intracellular signaling systems by high-density lipoproteins. <i>Journal of Clinical Lipidology</i> , 2010, 4, 376-381.	1.5	16
153	Epicardial Steatosis, Insulin Resistance, and Coronary Artery Disease. <i>Heart Failure Clinics</i> , 2012, 8, 671-678.	2.3	16
154	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. <i>Vascular Health and Risk Management</i> , 2016, 12, 185.	2.2	16
155	IMPROVE-IT. <i>Current Opinion in Cardiology</i> , 2016, 31, 426-433.	1.8	16
156	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. <i>Archives of Medical Research</i> , 2019, 50, 362-367.	3.5	16
157	Impact of Expanded FDA Indication for Icosapent Ethyl On Enhanced Cardiovascular Residual Risk Reduction. <i>Future Cardiology</i> , 2021, 17, 155-174.	1.0	16
158	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1703-1715.	2.7	16
159	Dysfunctional HDL: the journey from savior to slayer. <i>Clinical Lipidology</i> , 2014, 9, 49-59.	0.4	15
160	An Update on the Benefits and Risks of Rosuvastatin Therapy. <i>Postgraduate Medicine</i> , 2014, 126, 7-17.	2.0	15
161	Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. <i>Clinical Therapeutics</i> , 2016, 38, 603-609.	2.2	15
162	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). <i>Journal of Clinical Lipidology</i> , 2015, 9, 676-683.	1.5	14

#	ARTICLE	IF	CITATIONS
163	Statin Combination Therapy and Cardiovascular Risk Reduction. <i>Future Cardiology</i> , 2016, 12, 289-315.	1.0	14
164	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. <i>Archives of Medical Science</i> , 2020, 16, 1279-1287.	0.9	14
165	Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1437-1449.	5.5	14
166	When high is low: Raising low levels of high-density lipoprotein cholesterol. <i>Current Cardiology Reports</i> , 2008, 10, 488-496.	2.8	13
167	Recommendations for the Management of Patients with Familial Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015, 17, 473.	4.7	13
168	Changes in lipoprotein subfractions following menopause in the Longitudinal Study of Adult Health (ELSA-Brasil). <i>Maturitas</i> , 2019, 130, 32-37.	2.5	13
169	Elevated Triglycerides (≥ 150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 533-538.	2.2	13
170	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	5.2	13
171	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 125.	6.8	13
172	CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 641-651.	5.9	13
173	Design and rationale of a nationwide screening analysis from the LIPIDOGram2015 and LIPIDOGEn2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.9	12
174	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 594-605.	1.5	11
175	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1290-1297.e1.	1.5	11
176	Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis. <i>Clinical Cardiology</i> , 2019, 42, 908-913.	1.9	11
177	Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100086.	3.4	11
178	REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Medical Research Council Australian Diabetes, Obesity and Lifestyle Study) [Overlock 10 Tf]. <i>Journal of Clinical Lipidology</i> , 2021, 15, 1-11.	1.5	11
179	Triglycerides and Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3042-3045.	5.5	11
180	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGram 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	2.5	11

#	ARTICLE	IF	CITATIONS
181	Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. <i>Vascular Health and Risk Management</i> , 2010, 6, 1065.	2.2	10
182	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1365-1370.	2.4	10
183	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 754-761.	1.5	10
184	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era—Results from a racially diverse Brazilian cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 804-811.e2.	1.5	10
185	Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients. <i>Experimental Biology and Medicine</i> , 2019, 244, 1089-1095.	2.4	10
186	Composite acute phase glycoproteins with coronary artery calcification depends on metabolic syndrome presence—The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Cardiology</i> , 2019, 73, 408-415.	1.9	10
187	Branched-chain amino acids predict incident diabetes in the Brazilian Longitudinal Study of Adult Health—ELSA-Brasil. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108747.	2.8	10
188	Is HPS2-THRIVE the death knell for niacin?. <i>Journal of Clinical Lipidology</i> , 2015, 9, 343-350.	1.5	9
189	All-Cause and Acute Pancreatitis Health Care Costs in Patients With Severe Hypertriglyceridemia. <i>Pancreas</i> , 2017, 46, 57-63.	1.1	9
190	Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 1-9.	2.3	9
191	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study). <i>Lipids in Health and Disease</i> , 2020, 19, 237.	3.0	9
192	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. <i>Postgraduate Medicine</i> , 2021, 133, 125-139.	2.0	9
193	Ten things to know about ten imaging studies: A preventive cardiology perspective (—ASPC top ten) Tj ETQq1 1 0,784314,rgBT /O	3.4	9
194	Real-world Analyses of Patients With Elevated Atherosclerotic Cardiovascular Disease Risk From the Optum Research Database. <i>Future Cardiology</i> , 2021, 17, 743-755.	1.0	9
195	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, e023136.	3.8	9
196	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. <i>American Journal of Cardiology</i> , 2016, 118, 19A-32A.	1.5	8
197	Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 90.	1.8	8
198	Pleiotropic Effects of Angiotensin Receptor Blockers: Addressing Comorbidities by Optimizing Hypertension Therapy. <i>Journal of Clinical Hypertension</i> , 2011, 13, 42-51.	2.2	7

#	ARTICLE	IF	CITATIONS
199	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016, 118, 1812-1820.	1.5	7
200	Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 997-1007.e8.	1.5	7
201	Relation Between Cardiology Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin Adherence (from the Veterans Affairs Health Care System). <i>American Journal of Cardiology</i> , 2019, 124, 1165-1170.	1.5	7
202	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 741-747.e11.	1.5	6
203	That Myalgia of Yours Is Not From Statin Intolerance. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1223-1226.	5.5	6
204	Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007-2014. <i>Cardiology Journal</i> , 2019, 26, 604-606.	1.3	6
205	Eliminating atherosclerotic cardiovascular disease residual risk. <i>European Heart Journal</i> , 2023, 44, 4731-4733.	2.2	6
206	The Potential Role of Prasugrel in Secondary Prevention of Ischemic Events in Patients with Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2009, 121, 59-72.	2.0	5
207	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. <i>Journal of Clinical Lipidology</i> , 2015, 9, 511-518.e5.	1.5	5
208	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1873-1875.	5.5	5
209	Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Clinical Cardiology</i> , 2016, 39, 215-222.	1.9	5
210	PCSK9 and Lipoprotein(a). <i>Circulation Research</i> , 2016, 119, 3-6.	6.5	5
211	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2017, 33, 869-876.	1.9	5
212	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 92, .	0.2	5
213	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 261-271.	3.1	5
214	Differentiating EPA from EPA/DHA in cardiovascular risk reduction. <i>American Heart Journal Plus</i> , 2022, 17, 100148.	0.6	5
215	Coronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: A Multicohort Study. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.8	5
216	Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction. <i>Current Diabetes Reviews</i> , 2012, 8, 219-228.	1.3	4

#	ARTICLE	IF	CITATIONS
217	Glucolipototoxicity and the Heart. <i>Heart Failure Clinics</i> , 2012, 8, xvii-xviii.	2.3	4
218	JCL Roundtable: HDL in the primary care setting. <i>Journal of Clinical Lipidology</i> , 2014, 8, 364-372.	1.5	4
219	Differences in HDL particle size in the presence of subclinical thyroid dysfunctions: The ELSA-Brasil study. <i>Atherosclerosis</i> , 2020, 312, 60-65.	0.8	4
220	Unfavorable Triglyceride-rich Particle Profile in Subclinical Thyroid Disease: A Cross-sectional Analysis of ELSA-Brasil. <i>Endocrinology</i> , 2021, 162, .	2.8	4
221	Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines.. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100186.	3.4	4
222	The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease. <i>European Cardiology Review</i> , 0, 18, .	2.2	4
223	2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?. <i>Archives of Medical Science</i> , 0, , .	0.9	4
224	Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 346-351.	3.0	3
225	Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100087.	3.4	3
226	Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease. <i>American Journal of Preventive Cardiology</i> , 2022, 11, 100372.	3.4	3
227	The association between triglyceride-rich lipoproteins, circulating leukocytes, and low-grade inflammation: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Clinical Lipidology</i> , 2023, 17, 261-271.	1.5	3
228	Is the Guideline Process Replicable and, if Not, What Does This Mean?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 3-9.	3.6	2
229	Lipoprotein Subfractions in Patients with Acute Coronary Syndromes: Should we Reach Beyond LDL-C?. <i>Current Vascular Pharmacology</i> , 2019, 17, 376-378.	1.5	2
230	Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100040.	3.4	2
231	Recommendations of statin treatment after acute coronary syndrome: Hungarian experiences. <i>Atherosclerosis</i> , 2020, 303, 53-54.	0.8	2
232	Familial Hypercholesterolemia and Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2020, 75, 2694-2697.	5.5	2
233	Atherogenesis and Vascular Biology. <i>Contemporary Cardiology</i> , 2021, , 11-34.	0.0	2
234	Stroke Prevention in Patients With Atrial Fibrillation: Focus on New Oral Anticoagulants. <i>Postgraduate Medicine</i> , 2013, 125, 155-161.	2.0	1

#	ARTICLE	IF	CITATIONS
235	Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review. <i>Annals of Medicine</i> , 2014, 46, 341-352.	3.8	1
236	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?. , 2015, , 179-190.		1
237	INCREASED INPATIENT MORTALITY FOR CARDIOVASCULAR PATIENTS DURING THE FIRST WAVE OF THE COVID-19 EPIDEMIC IN NEW YORK. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3042.	5.5	1
238	Statin Prescribing and Dosingâ€”Failure Has Become an Option. <i>JAMA Cardiology</i> , 2021, 6, 854.	6.3	1
239	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. <i>Biomarker Insights</i> , 2022, 17, 117727192110667.	2.8	1
240	New approaches to triglyceride reduction: Is there any hope left?. <i>American Journal of Preventive Cardiology</i> , 2024, 18, 100648.	3.4	1
241	What is sufficient drug therapy for lipoprotein elevations?. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1300-1308.	1.5	0
242	Response to â€œTrends in Obesity, NHANES 2003â€”2004 to 2013â€”2014: Is Waist Circumference Increasing Independently of Body Mass Index?â€• <i>Obesity</i> , 2019, 27, 1044.	3.1	0
243	Management of Dyslipidemia. <i>Contemporary Cardiology</i> , 2019, , 39-69.	0.0	0
244	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. <i>Contemporary Cardiology</i> , 2021, , 1-22.	0.0	0
245	ASPC Presidentâ€™s Page: Addressing Unmet Needs in Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100155.	3.4	0
246	ASPC President's Page: Advancing and Refining Cardiovascular Disease Prevention. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100194.	3.4	0
247	Celebrating ASPC's achievements and introducing new educational offerings. <i>American Journal of Preventive Cardiology</i> , 2021, 7, 100226.	3.4	0
248	Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition. <i>Contemporary Cardiology</i> , 2021, , 269-294.	0.0	0
249	The bandwidth of preventive cardiology continues to increase: Meeting the challenge head on. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100132.	3.4	0
250	Substantially elevated TSH, not traditional clinical subclinical thyroid disorder groupings, are associated with smaller LDL-P mean size: ELSA-Brasil. <i>Journal of Clinical Lipidology</i> , 2022, , .	1.5	0
251	President's page: ASPC is leading the way in preventive cardiology. <i>American Journal of Preventive Cardiology</i> , 2022, 9, 100321.	3.4	0
252	ASPC president's page: Getting back to basics one patient at a time. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100350.	3.4	0

#	ARTICLE	IF	CITATIONS
253	Editorial commentary: Is it really a slam-dunk that reducing Lp(a) will decrease risk for cardiovascular events? Not so fast. Trends in Cardiovascular Medicine, 2024, 34, 200-202.	5.2	0
254	Dickkopf-1: an emerging danger signal in hypertension and cardiovascular disease. European Heart Journal, 2024, 45, 704-706.	2.2	0
255	Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. Obesity Pillars, 2024, 10, 100108.	3.3	0
256	It is Time to Address the Contribution of Cholesterol in all APOB-Containing Lipoproteins to Atherosclerotic Cardiovascular Disease. European Heart Journal Open, 0, , .	2.3	0
257	Branched-Chain Amino Acids, Alanine, and Thyroid Function: A Cross-Sectional, Nuclear Magnetic Resonance (NMR)-Based Approach from ELSA-Brasil. Metabolites, 2024, 14, 437.	3.0	0
258	Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS) - study design and methodology.. Archives of Medical Science, 0, , .	0.9	0
259	Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?. Expert Review of Cardiovascular Therapy, 0, , 1-17.	1.5	0